Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:37:05.943Z.
Calculation as of: 2026-10-06T20:37:05.943Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4147f1633fe526555426f89ecb5945f37dfc8ef4561f7e6db8f1148c00751c21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$5.79B
EV/FCF Ratio
N/A
TTM Avg
1.02x
3Y Avg
1.02x
5Y Avg
1.02x
Market Cap
$5.87B
EV/FCF Ratio
31.17x
TTM Avg
30.49x
3Y Avg
54.15x
5Y Avg
54.33x
Market Cap
$5.95B
EV/FCF Ratio
46.25x
TTM Avg
89.11x
3Y Avg
55.49x
5Y Avg
41.54x
Market Cap
$5.52B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | N/A | 1.02x | 1.02x | 1.02x |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 31.17x | 30.49x | 54.15x | 54.33x |
| GRAIL Inc. (GRAL)vs › | $5.89B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 46.25x | 89.11x | 55.49x | 41.54x |
| RadNet, Inc. (RDNT)vs › | $5.53B | N/A | 97.76x | 95.40x | 108.34x |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | N/A | N/A | N/A | N/A |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | 10.43x | 10.43x | 10.43x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
